Akcea Therapeutics Inc., of Cambridge, Mass., an affiliate of Ionis Pharmaceuticals Inc., said it filed a new drug submission (NDS) to Health Canada for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome (FCS).